Rigel Pharmaceuticals (RIGL) Interest Expenses (2010 - 2026)

Rigel Pharmaceuticals' Interest Expenses history runs 17 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• On a quarterly basis, Interest Expenses fell 84.68% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $2.4 million, a 84.68% decrease from a year earlier, with the FY2025 full-year figure at $46.7 million, down 85.82% from the prior year.
• Interest Expenses slipped to $2.4 million in Q1 2026 per RIGL's latest filing, from $6.9 million in the prior quarter.
• Across five years, Interest Expenses topped out at $17.7 million in Q1 2024 and bottomed at $1.1 million in Q4 2022.
• The 5-year median for Interest Expenses is $6.9 million (2025), against an average of $8.4 million.
• Across the five-year window, Interest Expenses soared 1020.65% in 2024 and slumped 84.68% in 2026, its largest moves.
• Year by year, Interest Expenses stood at $1.1 million in 2022, then soared by 137.85% to $2.6 million in 2023, then surged by 177.25% to $7.3 million in 2024, then slipped by 5.48% to $6.9 million in 2025, then tumbled by 65.93% to $2.4 million in 2026.
• Per Business Quant, the three latest RIGL Interest Expenses figures stand at $2.4 million (Q1 2026), $6.9 million (Q4 2025), and $15.3 million (Q3 2025).